How have DRMAW shares performed in 2024?

Dermata Therapeutics' stock was trading at $0.0070 at the start of the year. Since then, DRMAW stock has increased by 37.1% and is now trading at $0.0096. View the best growth stocks for 2024 here .

Are investors shorting Dermata Therapeutics?

Dermata Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 11,000 shares, an increase of 15.8% from the March 31st total of 9,500 shares. Based on an average daily trading volume, of 5,100 shares, the days-to-cover ratio is currently 2.2 days. View Dermata Therapeutics' Short Interest .

How do I buy shares of Dermata Therapeutics?

Shares of DRMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DRMAW

Dermata Therapeutics (DRMAW) Stock Price, News & Analysis

→ Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad)

Free DRMAW Stock Alerts

$0.0096

-0.01 (-51.02%)

(As of 05/3/2024 ET)

Compare

Today's Range: $0.0096
▼
$0.0170
50-Day Range: $0.0092
▼
$0.0179
52-Week Range: $0.01
▼
$0.04

Volume: 12,377 shs
Average Volume: 9,899 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get Dermata Therapeutics alerts:

Ad Banyan Hill Publishing

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

DRMAW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DRMAW Stock News Headlines

May 1, 2024 | americanbankingnews.com

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Short Interest Update

December 5, 2022 | finanznachrichten.de

Dermata Therapeutics: Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

May 5, 2024 | Banyan Hill Publishing (Ad)

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

December 5, 2022 | finance.yahoo.com

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

See More Headlines

Receive DRMAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:DRMAW
CUSIP: N/A
CIK: 1853816
Web: www.dermatarx.com
Phone: 858-800-2543
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Gerald T. Proehl (Age 65)
Founder, President, CEO & Chairman
Comp: $392k
Mr. David F. Hale (Age 75)
Co-Founder & Lead Independent Director
Comp: $73k
Ms. Kyri K. Van Hoose CPA (Age 46)
M.B.A., Senior VP & CFO
Comp: $415.8k
Dr. Christopher J. Nardo M.P.H. (Age 59)
Ph.D., Senior VP & Chief Development Officer
Comp: $443.52k
Mr. Sean Proehl
Senior Director of Legal & Business Development
Dr. Maria Bedoya Toro Munera M.B.A. (Age 73)
Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance
Comp: $27.04k

Key Competitors

View All Competitors

DRMAW Stock Analysis - Frequently Asked Questions

How have DRMAW shares performed in 2024?: Dermata Therapeutics' stock was trading at $0.0070 at the start of the year. Since then, DRMAW stock has increased by 37.1% and is now trading at $0.0096.
View the best growth stocks for 2024 here.
Are investors shorting Dermata Therapeutics?: Dermata Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 11,000 shares, an increase of 15.8% from the March 31st total of 9,500 shares. Based on an average daily trading volume, of 5,100 shares, the days-to-cover ratio is currently 2.2 days.
View Dermata Therapeutics' Short Interest.
How do I buy shares of Dermata Therapeutics?: Shares of DRMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRMAW) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial